The COVID-19 Vaccine Market Dashboard showcases supply information on COVID-19 vaccines, including th production capacity volumes, and doses secured through bilateral and multilateral agreements. All information supplemented with preliminary manufacturers' responses to UNICEF's Expression of Interest

Pipeline: A view of the latest COVID-19 vaccine development pipeline

Capacity: Reported COVID-19 vaccine production capacity volumes

Agreements: Bilateral/multilateral, local manufacturing and distribution supply agreements

Price: Reported COVID-19 vaccine price per dose

Number of vaccines approved for use

10

Reported global vaccine production volumes in 2021

19bn

Number of secured vaccine doses

9.0bn

Number o secured and for the COVA

The data found in this dashboard has been produced and processed from sources believed to be reliable. While the data is provided in good faith and to the it being up to date. While every effort is made to ensure the data quality, the data is provided "as is". The burden of fitness of the data lies completely with t any reported findings are not the responsibility of UNICEF. UNICEF does not make any warranty, express or implied, including warranties of fitness for a par responsibility for the accuracy, completeness, reliability or usefulness of any information provided (either isolated or in the aggregate), or represents that its

Nothing arising from the data should be taken to constitute UNICEF's advice or a formal recommendation. The information contained in the dashboard doe warranty of fitness or recommendation by UNICEF of any company or product for any purpose, and does not imply preference over products of a similar national company or product for any purpose, and does not imply preference over products of a similar national company or product for any purpose, and does not imply preference over products of a similar national company or product for any purpose, and does not imply preference over products of a similar national company or product for any purpose, and does not imply preference over products of a similar national company or product for any purpose, and does not imply preference over products of a similar national company or product for any purpose, and does not imply preference over products of a similar national company or product for any purpose, and does not imply preference over products of a similar national company or product for any purpose, and does not imply preference over products of a similar national company or product for any purpose, and does not imply preference over products of a similar national company or product for a similar national compa warrant that the products listed are of acceptable quality, have obtained regulatory approval in any country, or that their use is otherwise in accordance with but not limited to patent laws. Inclusion of products in the database does not imply any approval by UNICEF of the products in question (which is the sole p this dashboard should therefore be interpreted with caution and should not be used to guide country decision-making.





* Includes one billion doses of vaccines in the COVAX R&D Portfolio that COVAX has first right of refusal access to thro from the manufacturing processes under development), subject to technical success and regulatory approval.

apacity Agreements

ments Price

e development pipeline, reported global on is compiled from public sources and

f doses optioned X facility bn

Range of reported vaccine price per dose

\$2.19 - \$44

e best of UNICEF's knowledge, UNICEF does not commit to the user. The accuracy of any user's statistical analysis and ticular purpose, or assumes any legal liability or s use would not infringe privately owned rights.

s not in any way imply an endorsement, certification, cure that are not mentioned. UNICEF furthermore does not the national laws and regulations of any country, including rerogative of national authorities). The data contained in

ugh R&D partnership agreements (based on current estimates

